Open-house pharmaceutical discount agreements for epinephrine, excluding the nasal dosage form (ATC C01CA24)

Summary

This is an open-house model for non-exclusive pharmaceutical discount agreements concerning epinephrine, excluding the nasal dosage form, under ATC code C01CA24. The contracting authority intends to conclude identical, non-negotiable agreements with all interested pharmaceutical companies that meet the stated eligibility conditions; there is no selection between competing offers. The earliest possible contract start is 1 November 2026, and all agreements end on 31 October 2028. Agreements may be concluded during the term, but no later than 3 September 2028, and may be terminated with one month’s notice to the end of a month. The company must submit the required signed documents and verify its reliability and signing authority.